Common variable immunodeficiency (CVID) is a heterogeneous immunodeficiency syndrome characterized by hypogammaglobulinemia, recurrent bacterial infections, and various immunologic abnormalities. The clinical presentation is generally that of recurrent pyogenic sinopulmonary infections.
Introduction
Common variable immunodeficiency (CVID) is a heterogeneous immunodeficiency syndrome characterized by hypogammaglobulinemia, recurrent bacterial infections of the upper and lower respiratory tract, and various immunologic abnormalities. These infections are a direct result of the deficiency in antibody production -specifically immunoglobulin G (IgG) -that is the hallmark of this syndrome (1) (2) (3) (4) (5) (6) . Amongst populations of European origin, antibody defects are the most frequent primary specific immunodeficiency diseases (7) (8) . The estimated prevalence of CVID ranges from 1:10 000 to 1:50 000 population (4) . Defective antibody formation is accompanied by decreased serum IgG concentrations (5375 mg dl 71 ) (7) and usually by decreased serum IgA and IgM concentrations, but other known causes of humoral immune defects should be excluded (4, 5, 9) . However, some authors consider the diagnosis of CVID with serum levels of IgG below 500 mg dl 71 (1) . Although the number of B-cells may be reduced, the findings in CVID are consistent with insufficient in-vivo stimulus for B-cell activation rather than an intrinsic failure of Bcells to differentiate (2) . Occasionally, a reduction of CD4 þ T cells can be seen (5) . Patients with CVID are susceptible to recurrent respiratory infections and also have an increased incidence of autoimmune diseases (pernicious anaemia, systemic lupus erythematosus, rheumatoid arthritis, Sjo¨gren's syndrome) and lymphoproliferative disorders (2) (3) (4) . Clinically, patients with CVID have recurrent bacterial infections of the respiratory tract, such as sinusitis, otitis media, bronchitis and pneumonia (8) . Recurrent pulmonary infections can lead to chronic diseases such as bronchiectasis and chronic airflow limitation (CAL) (6) . Early intravenous immunoglobulin replacement therapy (INIRT) has been shown to reduce substantially the number of sinopulmonary infections (9) .
We studied the prevalence of lung involvement and the response to INIRT in 19 patients with CVID.
Patients and methods
A total of 19 non-consecutive patients (12 men and seven women) of mean (SD) age 33 (17?1) years (range 12-69 years) who had been diagnosed with CVID and with ongoing INIRT were included in the study. The sample included patients with CVID diagnosed at the Departments of Allergology, Internal Medicine, Paediatrics and Pneumology of our hospital. At diagnosis, all patients showed a defective antibody formation, serum IgG concentration 5375 mg dl 71 and other known causes of humoral immune defects had been excluded. INIRT consisted of intravenous infusion of IgG, 300-600 mg kg 71 every 21 days, to maintain serum IgG concentration 4400 mg dl 71 . All patients gave informed consent to participate in the study and the protocol was approved by the Institutional Review Board.
In all patients, CVID-related clinical manifestations, particularly respiratory signs and symptoms, were determined by medical history and physical examination. Pneumonic event was defined by synchronous occurrence with acute febrile illness, purulent sputum and new infiltrate on chest X-ray. Onset of symptoms and date of CVID diagnosis, dose and duration of INIRT, and adverse reactions to intravenous immunoglobulin were recorded. Routine laboratory investigations included complete red and white blood cell counts with differential lymphocyte count, serum protein electrophoresis, measurement of serum immunoglobulins by nephelometry, serum complement concentrations, and circulating immune complexes. Blood cultures and sputum smears were also obtained in patients admitted to the hospital because of pneumonia or upper respiratory tract infection. All patients had sinus and chest radiographs and high-resolution computed tomography (HRCT) (CT General Electrics Medical System, Milwaukee, WI, U.S.A.) in order to confirm the presence of sinusitis and bronchiectasis. Both radiographs and HRCT were interpreted blindly and independently by a radiologist and a pulmonologist. A complete pulmonary function tests including forced spirometry (Collins GS, MA, U.S.A.) (the best of three manoeuvres was chosen) with bronchodilator test (with two puffs of salbutamol), carbon monoxide diffusing capacity (DL CO ) measured at rest using the single-breath carbon monoxide test using helium dilution method (Collins GS, MA, U.S.A.), and arterial blood gases (Radiometer ABL 520, Copenhagen, Denmark) were determined by total and pulmonary pletysmography (Collins BP, MA, U.S.A.) when required. Functional values are expressed as percentage of predicted according to theoretical standards of the European Respiratory Society.
STATISTICAL ANALYSIS
The Kolmogorov-Smirnov test was used to assess the normal distribution of variables. Quantitative variables are expressed as mean and standard desviation (SD), and categorical variables as percentages. The chi-square (w 2 ) test (with Fisher's exact test) was used to compare proportions and the Student's t-test or the Mann-Whitney test (or the Wilcoxon's test for paired data) were used for the comparison of means. Statistical significance was set at P50?05.
Results
The mean age at the onset of symptoms was 14?7 years, with a mean age at diagnosis of CVID of 23?2 years. At the time of diagnosis, mean serum concentrations of immunoglobulins were the following: 160 mg dl 71 for IgG, 530 mg dl 71 for IgM, 510 mg dl 71 for IgA, and 52 KU l 71 for IgE. No abnormalities were found in white blood cell counts. Thirteen (68%) of the 19 patients had a decreased level of B-cells and 15 (79%) patients a low CD4 þ /CD8 þ ratio. The absolute number of circulating T cells and serum complement levels were within normal limits. Circulating immune complexes were detected in three patients. At the time of inclusion in the study, mean duration of replacement therapy was 7?5 years. One patient was withdrawn because of an anaphylactic reaction to INIRT.
As shown in Table 1 , respiratory symptoms especially of the upper respiratory tract were the most frequent clinical manifestations (100% of patients). Before replacement therapy, 84% of patients had suffered from at least one episode of lower respiratory tract infection and 74% had recurrent episodes of pneumonia. Episodes of lower respiratory tract infection per patient and year decreased from 0?28 before INIRT to 0?16 after it (P50?001). The most common causative pathogens were: Streptococcus pneumoniae in 37% of cases and Haemophilus influenzae in 26%. Pseudomonas aeruginosa, Staphylococcus aureus and Corynebacterium spp. were only isolated in patients with bronchiectasis. However Candida albicans and Cladosporium spp. were isolated in patients without bronchiectasis. Mycobacterium tuberculosis and Pneumocystis carinii were isolated in two patients. The prevalence of chronic lung involvement (bronchiectasis or CAL) was 68?5% in our patients. Bronchiectasis, the most common radiological finding, was diagnosed in 11 (58%) cases. Parenchymal scarring in five patients, pleural thickening in three and atelectasis in one, were less frequently seen. With regard to bronchiectasis, the left lower lobe was the most frequently involved (n = 8) followed by the lingula (n = 7) right lower lobe (n = 6), right middle lobe (n = 6), and right upper lobe (n = 1), and were multi-lobar in eight cases and bilateral in seven patients. Patients with bronchiectasis showed a moderate impairment of lung function as compared with patients without bronchiectasis ( Table 2 ). These two groups of patients showed statistically significant differences in the mean (SD) values FEV 1 
Discussion
CIVD is a heterogeneous primary immunodeficiency disease in which B-cells produce little or no antibody. This rare syndrome affects men and women equally. The disorder may occur at any age, but in most patients onset is in the second or third decade of life (4-7). Patients with CVID have recurrent sinopulmonary infections, such as sinusitis, otitis media, bronchitis and pneumonia as a direct result of deficiency in IgG production. It has been reported that 90% of patients with CVID suffer from one or more episodes of acute lower respiratory tract infection throughout their life, 89% from chronic sinusitis and 70% from recurrent otitis media (8) . In the present series, 84% of patients had at least one episode of pneumonia, 74% recurrent episodes of pneumonia and 63% of otitis media or sinusitis. Encapsulated bacteria are the commonest pyogenic agents isolated in CVID patients; the most feasible is that IgG -the major heat-stable opsonin of extracellular fluid-plays an important role in host defence against these pathogens.If serum IgG level falls, encapsulated bacteria are likely to be present (5) . Pseudomonas aeruginosa and Staphylococcus aureus account for most of the respiratory infections in patients with bronchiectasis (6); Streptococcus pneumoniae and Haemophilus influenzae are found in those without it (7) . The prevalence of infections by Mycobacterium tuberculosis and Pneumocistis carinii is low in CIVD, whereas these micro-organisms are usually present in other immunological disorders (2) (3) (4) ; this is probably due to the near normal serum CD4 þ T cell count in CIVD which is enough to prevent the development of these infections which usually occur when CD4 þ T cell levels are very low (2) (3) (4) . Our findings are similar to those previously reported, since respiratory infections are usually caused by S. pneumoniae and H. influenzae, and P. aeruginosa and S. aureus were only isolated in patients with bronchiectasis. The effectiveness of INIRT to reduce the number of sinopulmonary infections has been extensively documented (10, 11) . Our results support these findings since the number of pneumonic events decreased significantly in the patients of this study after INIRT. The absence of a control group constitutes a limitation in this study but we considered that placebo administration in patients with CVID was not ethical. It has been found that bronchiectasis were present in more than half of the patients with CVID (1, 12, 13) . In the present study bronchiectasis was also the most common finding and a delay in INIRT existed in most of our patients. The high prevalence of bronchiectasis in our series (58%) might be due to several factors, including the low levels of serum immunoglobulins at diagnosis and the delay in both diagnosis and INIRT.
Functional respiratory impairment due to development of bronchiectasis and chronic obstructive pulmonary disease has been found in CVID patients, and both obstructive and restrictive patterns have been reported (1, 11, 14) . CAL can be seen in the early course of the disease while restriction seems to occur in an advanced stage of CIVD. More than 50% of our patients had CAL that was higher in those with widespread bronchiectasis. Thus, because of the close relationship between these disorders, our results are in agreement with those of other series (11, 14) . It should be noted that, almost 60% of the patients of the present study presented a decrease of DLCO, which remains unexplained since none of them had pulmonary fibrosis or emphysema and only one had a restrictive pattern (these are conditions where DLCO usually decreases). It may be postulated that a decrease in DLCO may be an early sign of structural damage. With regard to the changes on pulmonary function tests after INIRT, Watts et al.
(1) demonstrated that FVC and FEV 1 remained stable in adults receiving an adequate INIRT. Although patients with bronchiectasis showed significantly lower FVC and FEV 1 values when compared with patients without bronchiectasis, serial pulmonary function tests were not performed in our study and therefore we can not compare our results with those of Watts.
Almost 20% of patients with CVID will develop one or more autoimmune disease, probably because of the coexistence of a disease causing abnormal immune regulation and immunodeficiency (6) . On the other hand, there is a 30fold increase in the incidence of malignant lymphoma compared with the general population; almost 30% of patients with CVID will have benign lymphoproliferative disorders (13, 15) . We found only one patient with nodular lymphoid hyperplasia of the mediastinum in whom the diagnosis was established by mediastinoscopy; pathologically, nodules consisted of local accumulations of Blymphocytes organized into follicles. Other features in CVID include several types of arthritis, a sarcoid-like syndrome with disseminated non-caseating granulomata, a high incidence of herpes zoster, and a 50-fold augmentation of gastric carcinoma with regard to the general population (2, 6, 16) . However, none of these conditions were diagnosed in our patients.
In summary, serum immunoglobulin levels should be determined in young patients with recurrent sinopulmonary infections since early recognition of CVID is mandatory. The prevalence of lung involvement is high, so a HRCT and pulmonary function test should be carried out in all patients. Immunoglobulin replacement therapy reduces pneumonic episodes and should be instituted early in the course of the disease to prevent repeated sinopulmonary infections and the development of bronchiectasis.
